About us
Blueprint Genetics is a genetic testing company based in Helsinki, Seattle, and Dubai, with a customer base spanning over 70 countries. We provide world-class genetic diagnostics and clinical interpretation for rare inherited diseases in 14 medical specialties.

What we do

We do high quality genetics testing for a global clinical community. By combining a state-of-the-art laboratory process, the latest sequencing technology, AI empowered data-crunching tools and techniques, world-class professionals, and a holistic customer experience approach, we are leading the way in changing mainstream healthcare of tomorrow.

Our promise

We provide clinicians and their patients with comprehensive and high-quality tools and resources for diagnosis of genetic conditions. In doing so, we provide possibilities for targeted treatment and individualized care for patients.

Key facts

Based in




> 3000
Clinicians in 70 countries
Founded in
Quality Management
Clinical laboratory certification by US regulatory authority
All laboratory functions accredited by College of American Pathologists
ISO 15189
Our processes and documentation comply with the most widely used standards worldwide


Tommi is the CEO and co-founder of Blueprint Genetics, a clinical genetics company based in Helsinki, Seattle, and Dubai. He has been running Blueprint Genetics since the beginning and is responsible for sales management, business development, and financing. Tommi spends time in the San Francisco Bay Area regularly and is a regular speaker in life science and tech conferences in both the US and Europe. Prior to Blueprint Genetics, Tommi founded a data analytics company called Whitevector and grew it to the Nordics and UK. Tommi holds a MSc (Tech) from the Helsinki University of Technology where he studied business strategy and applied mathematics.
Juha is the laboratory director and chief medical officer of Blueprint Genetics. He is a co-founder of the company as well. Juha is responsible for supervising laboratory production and for designing new diagnostic tests. On a daily basis, he participates in the clinical evaluation of genetic findings and further develops the company's variant classification and interpretation practices in collaboration with a team of geneticists. Juha has an MD-PhD from the University of Turku. In 2006, Juha completed his fellowship program in clinical physiology and nuclear medicine. The following year, he became a docent. From 2007 to 2009, he joined the University of California San Francisco’s Cardiac Stem Cell Translational Development Program as a postdoctoral researcher and later as a research specialist. He also teaches at the University of Helsinki.
Samuel is the chief strategy officer at Blueprint Genetics as well as a co-founder of the company. He is an expert in genome analysis technologies and has extensive experience in bioinformatics and cancer genomics research. Samuel received his PhD from the University of Helsinki and completed his postdoctoral research at Stanford University. At Stanford, he developed high-throughput sequencing technologies such as Oligonucleotide-Selective Sequencing (OS-Seq™). He is an adjunct professor in genetics at the University of Helsinki, an author of several high-impact publications, and an inventor and patent holder of DNA sequencing methods.
Tero-Pekka is the chief medical officer, president, and a co-founder of Blueprint Genetics. He is based in San Francisco and in charge of North American operations. He designs diagnostic panels and mutation databases and works with clinical evaluation of genetic data. Tero-Pekka has an MD-PhD degree and is specialized in pediatrics and pediatric cardiology. He has a PhD in molecular and cellular biology as well. In 2007, he continued his research at Stanford University, School of Medicine. During his 3-year postdoctoral training at Stanford University School of Medicine, he focused on the molecular genetic mechanisms of cardiovascular diseases. He continued his cardiovascular research at the University of Helsinki as a principal investigator and the head of an academic research group.


NICER and Blueprint Genetics Collaborate to Improve Genetic Testing for Immunologic and Hematologic disorders

Apr 20, 2020

The North American Immuno-Hematology Clinical Education & Research (NICER) Consortium and Blueprint Genetics have collaborated together to assemble a genetic test with the highest diagnostic potential for patients with immunologic and hematologic disorders. The new “Comprehensive Immune and Cytopenia Panel,” which is performed on a whole exome sequencing backbone, will support the creation of a patient registry and innovative research in the field.

Read more

See all news

Subscribe to our newsletter

Last modified: 06.17.2020